Beigene Ltd (NASDAQ:BGNE) Shares Purchased by Sumitomo Mitsui Trust Holdings Inc.

Share on StockTwits

Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Beigene Ltd (NASDAQ:BGNE) by 14.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,070 shares of the company’s stock after purchasing an additional 19,714 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Beigene were worth $19,112,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in BGNE. Capital Investment Advisory Services LLC acquired a new position in Beigene in the second quarter valued at approximately $26,000. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Beigene by 24.8% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock valued at $55,000 after acquiring an additional 88 shares during the period. Riverhead Capital Management LLC lifted its holdings in Beigene by 28.6% in the second quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock valued at $56,000 after acquiring an additional 100 shares during the period. Flagship Harbor Advisors LLC acquired a new position in Beigene in the third quarter valued at approximately $58,000. Finally, Marshall Wace North America L.P. acquired a new position in Beigene in the first quarter valued at approximately $76,000.

In other news, insider Xiaodong Wang sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $170.00, for a total value of $170,000.00. Following the transaction, the insider now owns 7,585,628 shares in the company, valued at approximately $1,289,556,760. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy Yung-Cheng Chen sold 3,800 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $189.15, for a total value of $718,770.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $756,600. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,676 shares of company stock worth $9,343,855. Company insiders own 13.40% of the company’s stock.

A number of brokerages have issued reports on BGNE. Maxim Group boosted their price target on Beigene from $170.00 to $210.00 and gave the company a “buy” rating in a report on Monday, November 4th. BidaskClub upgraded Beigene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. ValuEngine cut Beigene from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 17th. Guggenheim set a $205.00 price target on Beigene and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, Morgan Stanley dropped their target price on Beigene from $201.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $192.67.

BGNE opened at $199.44 on Friday. Beigene Ltd has a 12-month low of $108.00 and a 12-month high of $200.00. The firm has a market cap of $9.02 billion, a price-to-earnings ratio of -16.41 and a beta of 1.00. The company has a current ratio of 6.46, a quick ratio of 6.28 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average price is $138.52 and its 200 day moving average price is $131.38.

Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.43) EPS for the quarter, beating analysts’ consensus estimates of ($3.01) by $1.58. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. The business had revenue of $243.35 million for the quarter, compared to the consensus estimate of $65.58 million. During the same quarter in the prior year, the business posted ($2.92) EPS. The business’s revenue for the quarter was up 360.8% on a year-over-year basis. On average, research analysts forecast that Beigene Ltd will post -11.49 earnings per share for the current year.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Article: What is a short straddle?

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beigene Ltd (NASDAQ:BGNE).

Institutional Ownership by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Duluth Sees Unusually Large Options Volume
Duluth Sees Unusually Large Options Volume
Liberty Tripadvisor Holdings Inc Series A Target of Unusually Large Options Trading
Liberty Tripadvisor Holdings Inc Series A Target of Unusually Large Options Trading
Oyster Point Pharma’s  Quiet Period Set To End  on December 10th
Oyster Point Pharma’s Quiet Period Set To End on December 10th
LHC Group  Reaches New 1-Year High on Analyst Upgrade
LHC Group Reaches New 1-Year High on Analyst Upgrade
Investors Buy High Volume of Mondelez International Call Options
Investors Buy High Volume of Mondelez International Call Options
Ra International Group PLC  Insider Andrew Bolter Buys 15,715 Shares of Stock
Ra International Group PLC Insider Andrew Bolter Buys 15,715 Shares of Stock


 
© 2006-2019 Zolmax.